

Can't find or tolerate Tacrolimus? Learn about alternative immunosuppressant medications your doctor may consider, including Cyclosporine and more.
Tacrolimus is the gold standard in transplant medicine — it's the most widely prescribed immunosuppressant for preventing organ rejection after kidney, liver, and heart transplants. But what happens when you can't get it? Maybe your pharmacy is out of stock, you're experiencing serious side effects, or the cost is simply too high.
Whatever the reason, it's important to know that alternatives exist. You should never stop or switch your immunosuppressant on your own — this article is meant to help you have an informed conversation with your transplant team. Let's look at what's out there.
Tacrolimus (brand names Prograf, Envarsus XR, Astagraf XL) is a calcineurin inhibitor. It works by blocking an enzyme called calcineurin in your immune system's T-cells. When calcineurin is blocked, T-cells can't activate properly, which prevents them from attacking your transplanted organ.
Tacrolimus is typically taken twice daily (immediate-release) or once daily (extended-release) and requires regular blood level monitoring to make sure the dose is within a safe and effective range. It's been the backbone of transplant immunosuppression since it was first approved in 1994.
For a full breakdown of how it works, see our article on Tacrolimus mechanism of action explained.
Cyclosporine is the other calcineurin inhibitor — and it was actually the first one approved for transplant use, before Tacrolimus came along. It works through a similar mechanism (blocking calcineurin) but binds to a different protein called cyclophilin instead of FKBP-12.
When it might be used:
Key differences from Tacrolimus:
Sirolimus is an mTOR inhibitor — a completely different class of immunosuppressant from Tacrolimus. Instead of blocking calcineurin, it inhibits a protein called mTOR that's involved in cell growth and division, which suppresses the immune response through a different pathway.
When it might be used:
Key things to know:
Everolimus is another mTOR inhibitor, closely related to Sirolimus. It's FDA-approved for preventing rejection in kidney and liver transplant recipients.
When it might be used:
Key things to know:
Belatacept is a newer option that works completely differently from both calcineurin inhibitors and mTOR inhibitors. It's a selective T-cell costimulation blocker — it prevents T-cells from becoming fully activated by blocking a key signal they need.
When it might be used:
Key things to know:
This cannot be stressed enough: do not stop or switch your immunosuppressant without your transplant team's guidance. Each of these medications has different dosing, monitoring requirements, and side-effect profiles. A switch requires careful planning, dose adjustments, and close blood level monitoring to keep your transplant safe.
If you're having trouble finding Tacrolimus, your first step should be trying to locate it at another pharmacy. Use Medfinder to search for Tacrolimus availability near you, or check our guide on how to find Tacrolimus in stock.
Tacrolimus remains the most widely used immunosuppressant after organ transplant for good reason — it's effective and well-studied. But if you can't get it or can't tolerate it, there are real alternatives. Cyclosporine, Sirolimus, Everolimus, and Belatacept each have their own advantages and trade-offs.
Talk to your transplant team about which option makes the most sense for your situation. And if cost is part of the equation, don't miss our article on how to save money on Tacrolimus.
For more about Tacrolimus itself — including side effects, dosing, and drug interactions — explore our other guides:
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.